Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 14;37(1):11.
doi: 10.1186/s43046-025-00267-1.

Health-related quality of life and survival of patients with hepatocellular carcinoma treated with transarterial chemoembolization and Yttrium-90

Kathryn Bress  1 , Patrick Bou-Samra  1 , Cramer J Kallem  1 , Allan Tsung  1 , Ellie Gammer  1 , David A Geller  1 , James W Marsh  1 , Jennifer L Steel  2   3   4
Affiliations

Health-related quality of life and survival of patients with hepatocellular carcinoma treated with transarterial chemoembolization and Yttrium-90

Kathryn Bress et al. J Egypt Natl Canc Inst. .

Abstract

Background: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. Due to the advanced stage in which HCC presents, most patients are only eligible for transarterial chemoembolization (TACE) or radioembolization (Y90). The purpose of this study is to examine the differences in survival and health-related quality of life (HRQOL) in patients diagnosed with HCC and treated with TACE or Y90.

Methods: Two hundred thirty-four patients with HCC were enrolled in studies examining HRQOL between 2003-2009. HRQOL was evaluated using the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep). Between-group differences were examined using chi-square and ANOVA. Survival was assessed using Kaplan-Meier and Cox regression analyses.

Results: Significant baseline differences between patients treated with TACE versus Y90 were found. Patients who received Y90 tended to be older (p < 0.001), female (p < 0.001), had fewer lesions (p = 0.03), had smaller tumors (p = 0.03), and were less likely to have vascular invasion (p = 0.04). After adjusting for demographic and disease-specific factors, no significant differences in HRQOL were observed at 3 months (p = 0.79) or 6 months (p = 0.75). Clinically meaningful differences were found, with the TACE group reporting greater physical, social, and emotional well-being at 3 and 6 months and greater overall HRQOL at 6 months. No significant differences in survival were found.

Conclusions: Treatment with TACE and Y90 was similar with regard to survival. However, TACE showed statistically and clinically meaningful benefits in physical, social/family, and emotional well-being. Further research is warranted to identify profiles of patients who may demonstrate a preferential response to either TACE or Y90.

Keywords: Health-related quality of life; Hepatocellular carcinoma; Radioembolization; Survival analysis; Transarterial chemoembolization.

Plain language summary

Hepatocellular carcinoma (HCC) is the fifth most common type of cancer worldwide. For most patients with HCC, two procedures known as transarterial chemoembolization (TACE) and radioembolization (Y90), represent their most promising treatment options. The purpose of this study is to examine the differences in survival and health-related quality of life (HRQOL) in patients diagnosed with HCC and treated with TACE or Y90. In this sample, patients treated with TACE reported better HRQOL in the domains of physical, social, and emotional well-being at 3- and 6 months post-treatment and greater overall HRQOL at 6 months. There were no significant differences in patient survival based on the type of treatment they received. More research is needed to identify what treatment factors and patient characteristics might be associated with better HRQOL after being treated with TACE or Y90.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: All procedures performed in these studies were approved by the University of Pittsburgh’s Institutional Review Board (IRB reference numbers: PRO07050143 and PRO0607041). All participants provided written informed consent. Consent for publication: All participants provided written informed consent. No identifying information is included in this publication. Competing interests: The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Between treatment group differences in health-related quality of life at 3 months follow-up
Fig. 2
Fig. 2
Between treatment group differences on health-related quality of life at 6 months
See this image and copyright information in PMC

References

    1. Bruix J, Cirera I, Calvet X, Fuster J, Bru C, Ayuso C, et al. Surgical resection and survival in western patients with hepatocellular carcinoma. J Hepatol. 1992;15(3):350–5. - DOI - PubMed
    1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer Statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96. - DOI - PubMed
    1. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–9. - DOI - PubMed
    1. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients. Cancer. 1985;56(4):918–28. - DOI - PubMed
    1. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatol Baltim Md. 2011;53(3):1020–2. - DOI - PMC - PubMed

LinkOut - more resources